Canadian Arthritis Patient Alliance (CAPA)

The Canadian Arthritis Patient Alliance (CAPA) has published a user-friendly and informative MTX resource. The document may be reviewed via this link: CAPA MTX Link […]

Read More…


Changes to the Ontario Drug Benefit (ODB) Formulary effective February 28, 2018

New Single Source Drugs Metoject Subcutaneous (methotrexate sodium) 17.5mg/0.35mL, 20mg/0.4mL, 22.5mg/0.45mL, 25mg/0.5mL Inj Sol – Pref Syr (MDX)   Changes to Limited Use (LU) Criteria Aclasta (zoledronic acid) (NOV) and Generics (DRR, TAR, […]

Read More…


Ontario Drug Benefit Formulary

(Received from the Ministry January 24, 2018) We are pleased to provide you with the Summary of Changes – January 2018 to Edition No. 43 of the Ontario Drug Benefit (ODB) Formulary / […]

Read More…


Employment Standards in Ontario

The Ministry of Ontario has developed a publication that outlines Employment Standards in Ontario. Please review via this link: Employment Standards in Ontario […]

Read More…


NIHB listed Metoject pre-filled syringes as open benefits on the Drug Benefit List!

Please see this an updated list via this link: NIHB Metoject pre-filled syringes […]

Read More…


Erelzi Products & Patients Weighing 63kg or Less

It was recently announced that Erelzi is now funded under the the Ontario Drug Benefit Program (ODBP) as a LU benefit for the following indications: RA, AS and pJIA. It was noted in […]

Read More…


OHIP+ Begins January 1, 2018

OHIP+ BEGINS JANUARY 1, 2018 FOR ALL ONTARIANS UNDER 25 YEARS OLD.  IMPORTANT INFORMATION FOR YOU AS A PRESCRIBER. If you haven’t signed up to be a TFA provider, please contact Sandy Kennedy: admin@ontariorheum.ca We […]

Read More…


Update from the MOHLTC on OHIP+ Children and Youth Pharmacare

August 14, 2017 Colleagues, We are pleased to share this update on OHIP+: Children and Youth Pharmacare (OHIP+) with you. You can count on regular OHIP+ emails like this as your source of […]

Read More…


Brenzys (etanercept) now has ODB limited use codes! Updated EAP Forms now avaiable

The ODB limited use codes are for the two indications of rheumatoid arthritis (LU # 499) and ankylosing spondylitis (LU # 498). Please note the following: New requests for Enbrel for those two […]

Read More…


Shortage of Parenteral Methotrexate (with preservative)

Click here for information on the Parenteral Methotrexate drug shortage: link  […]

Read More…